ClinicalTrials.govpublic full text
A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation
multiple myeloma, carfilzomib, lenalidomide, dexamethasone, daratumumab, salvage autologous hematopoietic cell transplantation, 17-493, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 892029
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.